Osivax

📍 Lyon, France🗓 Founded 2017👥 52 employees💰 Last funded May 2023
Biotechnology Research🌐 osivax.com
Website LinkedIn
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
6
Total investors
5
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
6
Investor activity2018–2023 · investors recorded per year
2018520231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Osivax?
Osivax has 6 investors on record on gritt.io, including 5 early-stage backers and 1 late-stage investors.
When did Osivax last raise funding?
The most recent investment in Osivax recorded on gritt.io was in May 2023.
When was Osivax founded?
Osivax was founded in 2017.
What industry is Osivax in?
Osivax operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Osivax based?
Osivax is headquartered in Lyon, France.